The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension

Nature Communications

Volumn 4, Issue , 2013, Pages

  McBryde, Fiona D ^a   Abdala, Ana P ^a   Hendy, Emma B ^a   Pijacka, Wioletta ^a   Marvar, Paul ^a   Moraes, Davi J A ^b   Sobotka, Paul A ^c   Paton, Julian F R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Coridea NC1 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSION; INHIBITION; NEUROLOGY; PRESSURE EFFECT; RODENT; TOXICITY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CAROTID BODY; CAROTID SINUS NERVE; CAROTID SINUS NERVE DENERVATION; CHEMORECEPTOR REFLEX; CONTROLLED STUDY; DENERVATION; DEPRESSOR RESPONSE; HYPERTENSION; KIDNEY DENERVATION; KIDNEY NERVE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; SENSITIZATION; SYMPATHETIC NERVE; SYMPATHETIC TONE; T LYMPHOCYTE;

ANIMALS; ARTERIAL PRESSURE; BAROREFLEX; CAROTID BODY; CAROTID SINUS; CELL MOVEMENT; DENERVATION; HEART; HYPERTENSION; KIDNEY; MALE; RATS; RATS, INBRED SHR; RATS, WISTAR; SYMPATHETIC NERVOUS SYSTEM; T-LYMPHOCYTES;

EID: 84884168560     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3395     Document Type: Article

References (62)

1. Anderson, E. A., Sinkey, C. A., Lawton, W. J. & Mark, A. L. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 14, 177-183 (1989).
2. Esler, M., Rumantir, M., Kaye, D. & Lambert, G. The sympathetic neurobiology of essential hypertension: disparate influences of obesity, stress, and noradrenaline transporter dysfunction? Am. J. Hypertens. 14, 139S-146S (2001).
3. Grassi, G. Sympathetic and baroreflex function in hypertension: implications for current and new drugs. Curr. Pharm. Des. 10, 3579-3589 (2004).
4. Grassi, G. Counteracting the sympathetic nervous system in essential hypertension. Curr. Opin. Nephrol. Hypertens. 13, 513-519 (2004).
5. Smith, P. A., Graham, L. N., Mackintosh, A. F., Stoker, J. B. & Mary, D. A. Relationship between central sympathetic activity and stages of human hypertension. Am. J. Hypertens. 17, 217-222 (2004).
6. Fisher, J. P. & Paton, J. F. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J. Hum. Hypertens. 26, 463-475 (2012).
7. Falaschetti, E., Chaudhury, M., Mindell, J. & Poulter, N. Continued improvement in hypertension management in England: results from the Health Survey for England. Hypertension 53, 480-486 (2006).
8. Plump, A. Accelerating the pulse of cardiovascular R&D. Nat. Rev. Drug. Discov. 9, 823-824 (2010).
9. Myat, A., Redwood, S. R., Qureshi, A. C., Spertus, J. A. & Williams, B. Resistant hypertension. BMJ 345, e7473 (2012).
10. Pimenta, E. & Calhoun, D. A. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 125, 1594-1596 (2012).
11. Abdala, A. P. et al. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J. Physiol. 590, 4269-4277 (2012).
12. Hering, D. et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J. Hypertens. 25, 157-161 (2007).
13. Narkiewicz, K. et al. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 97, 943-945 (1998).
14. Paton, J. F. et al. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 61, 5-13 (2013).
15. Tan, Z. Y. et al. Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circ. Res. 106, 536-545 (2010).
16. Chua, T. P. et al. Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur. Heart. J. 18, 480-486 (1997).
17. Narkiewicz, K. et al. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 99, 1183-1189 (1999).
18. Ponikowski, P. et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation 104, 544-549 (2001).
19. Sun, S. Y., Wang, W., Zucker, I. H. & Schultz, H. D. Enhanced peripheral chemoreflex function in conscious rabbits with pacing-induced heart failure. J. Appl. Physiol. 86, 1264-1272 (1999).
20. Sun, S. Y., Wang, W., Zucker, I. H. & Schultz, H. D. Enhanced activity of carotid body chemoreceptors in rabbits with heart failure: role of nitric oxide. J. Appl. Physiol. 86, 1273-1282 (1999).
21. Przybylski, J. Do arterial chemoreceptors play a role in the pathogenesis of hypertension? Med. Hypotheses. 7, 127-131 (1981).
22. Somers, V. K., Mark, A. L. & Abboud, F. M. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 11, 608-612 (1988).
23. Trzebski, A., Tafil, M., Zoltowski, M. & Przybylski, J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc. Res. 16, 163-172 (1982).
24. Sinski, M. et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens. Res. 35, 487-491 (2012).
25. Esler, M. D. et al. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903-1909 (2010).
26. Hart, E. C. et al. Translational examination of changes in baroreceptor reflex function after bilateral renal denervation in hypertensive rats and humans. Hypertension 62, 533-541 (2013).
27. Brinkmann, J. et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 60, 1485-1490 (2012).
28. Prochnau, D. et al. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. Eurointervention 7, 1077-1080 (2012).
29. Vase, H. et al. Catheter-based renal denervation for treatment of resistant hypertension. Dan. Med. J. 59, A4439 (2012).
30. Harrison, D. G. et al. Inflammation, immunity, and hypertension. Hypertension 57, 132-140 (2011).
31. Muller, D. N., Kvakan, H. & Luft, F. C. Immune-related effects in hypertension and target-organ damage. Curr. Opin. Nephrol. Hypertens. 20, 113-117 (2011).
32. Zubcevic, J., Waki, H., Raizada, M. K. & Paton, J. F. Autonomic-immunevascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57, 1026-1033 (2011).
33. Waki, H. ,K., Li, B.-H., Kasparov, S., Murphy, D. & Paton, J. F. R. Over expression of junctional adhesion molecule-1 in nucleus tractus solitarii is prohypertensive in the rat. Hypertension 49, 1321-1327 (2007).
34. Xu, H. et al. Upregulation of junctional adhesion molecule-1 is associated with experimental and clinical hypertension. Cardiovasc. Res. 96, 552-560 (2012).
35. Kline, R. L., Stuart, P. J. & Mercer, P. F. Effect of renal denervation on arterial pressure and renal norepinephrine concentration in Wistar-Kyoto and spontaneously hypertensive rats. Can. J. Physiol. Pharmacol. 58, 1384-1388 (1980).
36. Winternitz, S. R., Katholi, R. E. & Oparil, S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J. Clin. Invest. 66, 971-978 (1980).
37. Jacob, F., Ariza, P. & Osborn, J. W. Renal denervation chronically lowers arterial pressure independent of dietary sodium intake in normal rats. Am. J. Physiol. Heart. Circ. Physiol. 284, H2302-H2310 (2003).
38. Norman, Jr. R. A. & Dzielak, D. J. Role of renal nerves in onset and maintenance of spontaneous hypertension. Am. J. Physiol. 243, H284-H288 (1982).
39. DiBona, G. F. & Esler, M. Translational medicine: the antihypertensive effect of renal denervation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R245-R253 (2010).
40. Prabhakar, N. R. & Semenza, G. L. Gaseous messengers in oxygen sensing. J. Mol. Med. 90, 265-272 (2012).
41. Schultz, H. D. Angiotensin and carotid body chemoreception in heart failure. Curr. Opin. Pharmacol. 11, 144-149 (2011).
42. Ding, Y., Li, Y. L. & Schultz, H. D. Role of blood flow in carotid body chemoreflex function in heart failure. J. Physiol. 589, 245-258 (2011).
43. Wyatt, C. N. et al. Key roles for AMP-activated protein kinase in the function of the carotid body? Adv. Exp. Med. Biol. 605, 63-68 (2008).
44. Ackland, G. L., Kazymov, V., Marina, N., Singer, M. & Gourine, A. V. Peripheral neural detection of danger-associated and pathogen-associated molecular patterns. Crit. Care. Med. 41, e85-e92 (2013).
45. Lam, S. Y. et al. Chronic intermittent hypoxia induces local inflammation of the rat carotid body via functional upregulation of proinflammatory cytokine pathways. Histochem. Cell. Biol. 137, 303-317 (2011).
46. Clarke, J., de Burgh Daly, M. & Ead, H. in Vascular Analysis Of The Carotid Body In The Spontaneously Hypertensive Rat. (eds Data, P.) 3-8 (Plenum Press, 1993).
47. Simms, A. E., Paton, J. F., Pickering, A. E. & Allen, A. M. Amplified respiratorysympathetic coupling in the spontaneously hypertensive rat: does it contribute to hypertension? J. Physiol. 587, 597-610 (2009).
48. Finley, J. C. & Katz, D. M. The central organization of carotid body afferent projections to the brainstem of the rat. Brain. Res. 572, 108-116 (1992).
49. Paton, J. F., Deuchars, J., Li, Y. W. & Kasparov, S. Properties of solitary tract neurones responding to peripheral arterial chemoreceptors. Neuroscience 105, 231-248 (2001).
50. Somers, V. K., Mark, A. L. & Abboud, F. M. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J. Clin. Invest. 87, 1953-1957 (1991).
51. Lohmeier, T. E. & Iliescu, R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 57, 880-886 (2011).
52. Heusser, K. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55, 619-626 (2010).
53. Cates, M. J., Steed, P. W., Abdala, A. P., Langton, P. D. & Paton, J. F. Elevated vertebrobasilar artery resistance in neonatal spontaneously hypertensive rats. J. Appl. Physiol. 111, 149-156 (2011).
54. Marvar, P. J., Lob, H., Vinh, A., Zarreen, F. & Harrison, D. G. The central nervous system and inflammation in hypertension. Curr. Opin. Pharmacol. 11, 156-161 (2011).
55. Marvar, P. J. et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ. Res. 107, 263-270 (2010).
56. Elenkov, I. J., Wilder, R. L., Chrousos, G. P. & Vizi, E. S. The sympathetic nerve: an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52, 595-638 (2000).
57. Niewinski, P. et al. Carotid body removal for treatment of chronic systolic heart failure. Int. J. Cardiol. doi: 10.1016/j.ijcard.2013.03.011 (2013).
58. Cornock, R., Langley-Evans, S. C., Mobasheri, A. & McMullen, S. The impact of maternal protein restriction during rat pregnancy upon renal expression of angiotensin receptors and vasopressin-related aquaporins. Reprod. Biol. Endocrinol. 8, 105 (2010).
59. Langley, S. C., Seakins, M., Grimble, R. F. & Jackson, A. A. The acute phase response of adult rats is altered by in utero exposure to maternal low protein diets. J. Nutr. 124, 1588-1596 (1994).
60. Loria, A. et al. Sex and age differences of renal function in rats with reduced ANG II activity during the nephrogenic period. Am. J. Physiol. Renal. Physiol. 293, F506-F510 (2007).
61. Guzik, T. J. et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204, 2449-2460 (2007).
62. Paton, J. F. A working heart-brainstem preparation of the mouse. J. Neurosci. Methods 65, 63-68 (1996).